All In Biotech

Free tool

FAERS Monitor: Empaveli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215014 or its brand name (Empaveli, Pegcetacoplan). Reports on generic versions are filed under their own applications.

Reports

1,188

Serious

796

67% of reports

Hospitalization

329

Death reported

92

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue157
  • off label use142
  • haemoglobin decreased128
  • haemolysis109
  • breakthrough haemolysis96
  • headache75
  • drug ineffective67
  • product dose omission issue62
  • covid-1957
  • diarrhoea57
  • pyrexia56
  • platelet count decreased54
  • injection site pain53
  • condition aggravated52
  • malaise52

Reports by year received

View as table
YearReports
202122
202256
2023110
2024540
2025218
2026242

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,971 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
breakthrough haemolysisSignal965614.74495.1404,933
haemolysisSignal109253.5211.626,785
haemoglobin decreasedSignal12822.118.82,566
platelet count decreasedSignal549.06.9376
covid-19Signal575.84.5221
product dose omission issueSignal623.72.9123
fatigueSignal1573.63.1299
injection site painSignal533.12.472
condition aggravatedSignal523.02.370
off label useSignal1422.92.5179
pyrexiaSignal562.92.267
headacheSignal752.11.744
malaiseSignal522.11.629
diarrhoea571.61.211
drug ineffective670.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.